Business Wire

Lake House Group Chairman Donates 2.5 Million Masks to European Governments

29.4.2020 07:14:00 EEST | Business Wire | Press release

Share

In response to the impact of COVID-19 on European communities, Lake House Group Chairman Charles Brown has donated and coordinated delivery of 2.5 million masks to three European nations in order to stem the spread of the virus. He said “Masks are a low-cost, effective intervention for stopping the spread of the virus and getting people back to work safely.”

A Hong Kong native with European roots, Brown has donated one million masks each to the Kingdom of Spain and the Federal Republic of Germany, with an additional 500,000 masks designated for Région Sud in France. “The masks landed in Spain and Germany on 15 and 19 April, respectively, and the masks bound for southern France are currently in transit,” reported Torsten Hartmann, Managing Director for Europe in Lake House’s London office.

While traveling in Europe prior to widespread lockdowns, Brown noted with concern that few European citizens wore masks in public. Regarding Hong Kong’s low number of confirmed cases since the outbreak began there on 23 January, Brown stated “The 2003 SARS epidemic taught Hong Kongers to be vigilant about wearing masks, and that experience shows.”

The donation efforts have been spearheaded by Brian Lu, Venture Partner at the Japanese venture capital firm Infinity Ventures, in which Charles Brown is a Limited Partner. The firm’s portfolio company, Hong Kong-based logistics startup Buyandship, has worked to ensure the masks are delivered with as little burden as possible on the governments receiving the donations.

According to Lu, “We’ve seen how tough it’s been for governments to obtain masks from trusted sources and get them delivered efficiently, so we’re proud to be able to help these countries get masks into people’s hands as quickly as possible.”

“Giving money is an easy thing if you have it, but a more effective thing is to deliver the goods to the point where they are needed, and that’s what we’re trying to achieve here,” added Lake House’s Charles Brown. “I hope our efforts are able to spark other private donors to use their resources and connections to make similar efforts,” he said.

About Lake House Group

Established in 1995, Lake House Group is a private investment company founded by Hong Kong native Charles Brown, who is also Chairman Emeritus and Founding Board Member of the United Nations Peace Development Foundation in China. Lake House is led by CEO David Timblick, and invests in businesses across the globe at every stage. With offices in Hong Kong and London, the firm is involved in projects and investments in excess of US$15 billion across 15 countries.

About Infinity Ventures

Infinity Ventures is a venture capital firm, focused on early stage Internet companies, founded in Japan in 2008, with offices in Tokyo, Taipei, and Beijing. The firm manages $255M USD, and has invested in 91 startups and produced 9 IPOs. Since its founding, Infinity Ventures has grown alongside its portfolio companies to build category-leading innovators and unicorns including Groupon, Farfetch, freee, Yeahka, WealthNavi, and 17 Media.

About Buyandship

Buyandship is a cross-border e-commerce logistics company established in 2014. The company provides a one-stop transit service for goods bought in the United States, United Kingdom, Japan, Korea, and China. Buyandship currently maintains warehouses in multiple countries, with daily scheduled flights to Hong Kong and other markets in Asia.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Holly Harrington, Infinity Ventures
holly@infinityventures.com
+886936845447

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye